There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nkarta (NKTX – Research Report), Dianthus Therapeutics (DNTH – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Nkarta (NKTX)
TD Cowen analyst Yaron Werber maintained a Buy rating on Nkarta today. The company’s shares closed last Thursday at $12.98.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $19.25 average price target, a 45.9% upside from current levels. In a report issued on March 18, Leerink Partners also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Dianthus Therapeutics (DNTH)
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Dianthus Therapeutics today and set a price target of $44.00. The company’s shares closed last Thursday at $27.94, close to its 52-week high of $30.77.
According to TipRanks.com, CFA is a 5-star analyst with an average return of
Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.00.
Eli Lilly & Co (LLY)
In a report released today, Robyn Karnauskas from Truist Financial assigned a Buy rating to Eli Lilly & Co. The company’s shares closed last Thursday at $770.26, close to its 52-week high of $800.78.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $846.43, representing a 9.4% upside. In a report issued on March 7, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NKTX:
